Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
Side-by-side · Research reference

GHK-CuvsPinealon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticReviewed8/47 cited
BHuman-MechanisticDraft12/36 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
1–2 mgSQ dosePickart 2018
HumanMechanisticPickart 2018Zink 2003
HoursHalf-life
SQ or topical · Local · Daily or 2-3×/week
Pinealon
Pineal-derived · Neuroprotective
5–10 mgPer cycle doseKhavinson 2014
HumanMechanisticKhavinson 2014
HoursHalf-life (est)
SQ or IM · Daily for 10 days · 1-2×/year

01Mechanism of Action

Parameter
GHK-Cu
Pinealon
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
Replaces declining endogenous levels
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development

02Dosage Protocols

Parameter
GHK-Cu
Pinealon
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
Topical concentration
0.1–2.0% in serum / cream
Frequency
Daily or 2–3× per week (SQ)
Once daily during cycle
Lower / starter dose
0.5 mg / day SQ
2.5 mg / day
Evidence basis
Human-mechanistic + topical clinical studiesPickart 2018
Russian clinical trials + in vitroKhavinson 2014
Duration
8–12 weeks for visible skin / hair effect
10-day cycles, 1–2× per year
Reconstitution
Bacteriostatic water; light-protected
Bacteriostatic water
Timing
No specific time; evening preferred for topicals
No specific time
Half-life
Hours (estimated; rapid tissue uptake)
Hours
Standard dose
5–10 mg / day for 10 daysKhavinson 2014

04Side Effects & Safety

Parameter
GHK-Cu
Pinealon
Injection site reaction
Erythema, mild pruritus (common)
Mild irritation
Topical irritation
Mild redness, transient stinging
Copper accumulation
Theoretical with very high chronic doses
Allergic reaction
Rare hypersensitivity to copper
Pregnancy / OB
Avoid topical and SQ — insufficient data
Avoid
Wilson disease
Contraindicated
Long-term safety
Limited Western data
Absolute Contraindications
GHK-Cu
  • ·Wilson disease (copper-overload disorder)
  • ·Pregnancy / breastfeeding
  • ·Known copper hypersensitivity
Pinealon
  • ·Pregnancy / breastfeeding
Relative Contraindications
GHK-Cu
  • ·Hemochromatosis (copper-iron crosstalk theoretical)
  • ·Concurrent copper-chelator therapy
Pinealon
  • ·Active malignancy (theoretical via gene expression modulation)

05Administration Protocol

Parameter
GHK-Cu
Pinealon
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
SQ — abdomen preferred.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
Daily during cycle, any time.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
29–31G, 4–8 mm insulin syringe.

06Stack Synergy

GHK-Cu
+ BPC-157
Moderate
View BPC-157

GHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.

GHK-Cu
1–2 mg SQ · daily near wound
BPC-157
250–500 mcg SQ · daily near wound
Primary benefit
Combined ECM rebuilding + angiogenesis for tissue repair
Pinealon
+ Epitalon
Moderate
View Epitalon

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon
5–10 mg SQ · daily × 10 days
Epitalon
5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit
Neuroprotection + telomere preservation